Myto Health is offering blood-based diagnostic biomarkers for aging and neurodegeneration by interrogating ubiquitin pathway enzymes such as ubiquitin ligases to establish rapid, economical diagnostics.
The diagnostic test has been validated with patients that have mutations in genes that lead to PD. Application of this test for late onset of PD diagnosis includes up to one million patients in the USA alone.
Currently there is no blood-based test for diagnosis of PD. The blood-based diagnostic signatures of poly-ubiquitins will have broad diagnostic applications for early detection of Parkinson’s disease as well as other aging markers.
Patients in the USA alone represent the addressable late-onset Parkinson’s population lacking an accessible, non-invasive blood-based diagnostic test.
Because of the breadth and depth of the platform, translation of these products and services into clinic requires highly accomplished teams. Myto Health plans to share, partner, establish joint ventures, license, and seek investments to bring these technologies to patients and consumers.
Myto Health invites inquiries from collaborators, diagnostic organizations, and reference laboratories to explore these technologies, bring them to market pace, and ultimately benefit the patients.
Connect with our Business Development team in Malvern, PA to discuss assay integration or licensing.
